Eli Lilly's Denanamab and the Future of Alzheimer's Treatments

This chapter discusses the upcoming FDA decision on Eli Lilly's Alzheimer's treatment called Denanamab and compares its efficacy with another FDA-approved drug. It also explores Lilly's pricing and marketing strategies and the potential impact on the market for Alzheimer's treatments.

Transcript

Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app